IQVIA Holdings Inc. surged as transformative clinical data-analytics partnership news drove bullish sentiment; stocks have been trading up by 12.12 percent
Spot the Next Big Runner
Click Here for a Millionaire’s POV on Trading IQV
JOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- HSBC raised its price target on IQVIA to $240 from $210 and reiterated a Buy rating, expecting relative outperformance in healthcare in the second half of the year.
- Deutsche Bank named IQVIA a short-term “Catalyst Call: Buy” after about a 10% year-to-date slide, arguing fears about its business mix and AI/ML disruption are overstated.
- Multiple firms have lifted IQVIA targets into roughly the…
